Genentech/Roche and $BIIB line up bispecific antibodies against cancer
The first in a potential multibillion-dollar family of cancer-fighting drugs by Genentech Inc. could offer an off-the-shelf alternative to effective, but limited, cell therapies.
The treatment is called bispecific because the arms of the Y-shaped antibody, an artificial protein, can simultaneously link to two different players in the fight against cancer. That effectively offers a one-two punch against the disease. For now, the FDA approval gives doctors another tool beyond chimeric antigen receptor T cell, or CAR-T, therapies that have been lauded for their potency. CAR-Ts, such as Yescarta from Gilead Sciences Inc.'s Kite Pharma and Novartis AG's Kymriah, use a patient's own cells, which are re-engineered and infused back into them in a process that can take weeks.
Lunsumio — homegrown at Genentech research and early development, or gRED — is the first in what the company believes could be a family of bispecific antibodies that eventually could expand into first-line options for patients, not just for patients who have failed other therapies. "Both of these antibodies are new approaches for treating cancers," Laport said."They are off-the-shelf or ready-to-treat, unlike cell therapies with genetic engineering, and are given for a fixed duration, for a finite amount of time. Patients are less likely to develop side effects."
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Southwest reduces SFO, San Jose flight cancellations in return to normal - San Francisco Business TimesSouthwest Airlines Co. appears to be making good on a promise to resume its schedule after a week of mayhem for airline passengers in SFO, San Jose and around the country.
Weiterlesen »
4 San Diego homeless shelters open due to inclement weatherThe Inclement Weather Shelter Program for San Diegans experiencing homelessness was activated Saturday by the San Diego Housing Commission in partnership with the city of San Diego.
Weiterlesen »
FDA issues recall for select first aid, burn creamsThe FDA has issued a recall notice for select first aid kits and burn creams.
Weiterlesen »
FDA broke own protocols in approving Biogen Alzheimer’s drug, congressional report saysThe FDA failed to adhere to its own guidance and internal practices during the approval process for Biogen’s Alzheimer’s drug, which was “rife with irregularities,” a congressional report says.
Weiterlesen »
FDA Gives First Go Ahead for Lab Grown Meat ProductThe FDA has approved a lab grown meat product from Upside Foods for human consumption, which now only needs USDA approval before being sold to customers.
Weiterlesen »
House Dems Say FDA 'Inappropriately Collaborated' With Biogen on New Alzheimer's Drug'I am hopeful these findings are a wake-up call for FDA to reform its practices and a call to action to my congressional colleagues to continue oversight of the pharmaceutical industry to ensure they don't put profits over patients,' said Rep. Carolyn Maloney.
Weiterlesen »